Presseinformationen weltweit an Journalisten und Leser verbreiten
SIRION Biotech GmbH is proud to announce our achievement of ISO 9001:2015 certification by DEKRA. ISO 9001 is the worlds most widely recognized standard for a quality management system (QMS). It enables companies to operate more effectively on several different Mehr
SIRION Biotech, das führende deutsche Unternehmen für Virale Vektoren, präsentiert am 17. November 2021 ab 14.00 (GMT) ein Webinar zur Optimierung des Designs Lentiviraler Vektoren. Die Optimierung des Designs eines lentiviralen Konstrukts in einer frühen Entwicklungsphase ist die Basis für Mehr
SIRION Biotech, the leading German viral vector company, will present a Webinar on November 17 at 2 PM GMT discussing optimizing lentivirus vector design for improved quality and safety Optimizing the safety of lentiviral vectors has been one of the Mehr
The French Ministry of Higher Education, Research and Innovation have granted SIRION Biotech a 3-year CIR (Crédit Impôt Recherche) accreditation lasting until end of 2023. As a result, SIRION Biotech GmbH is now on a list of experts accessible on Mehr
SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Denali Therapeutics (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product Mehr
A recent collaboration between Associate Professor Peter Johannes Holst at University of Copenhagen, his research group and colleagues at Bogor Agricultural University, and Munich based viral vector company SIRION Biotech, demonstrated that their key candidate hAd19a/64 can outperform its counterpart Mehr
The viral vector specialist SIRION Biotech GmbH today announces the signing of a preferred partnership agreement with Heidelberg University Hospital and AAV pioneer Prof. Dirk Grimm. This strategic alliance will enable both partners to offer engineering of novel AAV capsids Mehr
SIRION Biotech GmbH and Vibalogics GmbH, have signed a strategic partnership agreement designed to meet demand from gene therapy companies for a start-to-finish Adeno-Associated Virus (AAV) service. The new service offering, which will be available from the beginning of 2018, Mehr
Die im Innovations- und Gründerzentrum für Biotechnologie (IZB) Martinsried ansässige SIRION Biotech GmbH meldet zu Jahresbeginn Profitabilität bei 140 prozentigem Umsatzwachstum auf über 4 Millionen Euro, rechtzeitig zum 10-jährigen Bestehen ihrer Geschäftstätigkeit. Maßgeblich ist eine erste große Meilensteinzahlung für die Mehr